Skip to Content

Dianeal PD-1 with 3.5% Dextrose (lvp solution) Disease Interactions

There are 2 disease interactions with Dianeal PD-1 with 3.5% Dextrose (lvp solution):


Sodium salts (Includes Dianeal PD-1 with 3.5% Dextrose) ↔ sodium/water imbalance

Severe Potential Hazard, Moderate plausibility. Applies to: Congestive Heart Failure, Fluid Retention, Hypernatremia, Hypokalemia

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.


  1. "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
  3. "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.

LVP solution (Includes Dianeal PD-1 with 3.5% Dextrose) ↔ hyperglycemia

Moderate Potential Hazard, Moderate plausibility. Applies to: Diabetes Mellitus

LVP solution for peritoneal dialysis contains dextrose and may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation or modification of antidiabetic therapy during treatment with these solutions. Blood glucose should me monitored.

More about Dianeal PD-1 with 3.5% Dextrose (lvp solution)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.